Demonstrates MSC-PLGA nanoparticles improve lysosomal function in Alzheimer's disease, suggesting a novel nanomedicine for therapy.
These results demonstrate that MSC-PLGA-NPs, a novel multifunctional nanoparticle platform, synergistically integrates the BBB penetration capability of MSC-NVs and the lysosomal acidification function of PLGA. The synergistic combination represents a pioneering "delivery-repair-clearance" integrated strategy for AD therapy. Offering significant advantages over single-component approaches, MSC-PLGA-NPs provide a promising preclinical candidate and new insight into lysosome-targeted nanomedicines for neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: